Lung Cancer Trial, Not Yet Recruiting NCT06613308 Sponsor: Capital Medical University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT06613308
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults between 18 and 75 years old.
  • People who have been newly diagnosed with a type of lung cancer called non-small cell lung cancer (stages IIA to IIIB), confirmed by a tissue sample, and whose cancer does not have certain specific genetic changes known as "driver gene" mutations.
  • People whose scans show at least one tumour that can be measured in a specific way used in cancer research (called RECIST 1.1).
  • People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are either fully active or have only minor limitations in physical activity.
  • People who have not previously had any systemic cancer treatment or radiotherapy.
  • People whose medical team, after a team-based review, has assessed them as suitable for surgery to remove the tumour, as well as for pre-surgery immune or chemotherapy treatment.
  • People who are willing and able to sign a written consent form before joining the study.
  • People whose lung function tests before joining confirm their lungs are working well enough to safely undergo surgery.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who decline to take part or are unable to give clear informed consent.
  • People who need ongoing treatment with steroid medications (such as cortisone or prednisone) or other medicines that suppress the immune system.
  • People who have used antibiotics in the three months before joining, or who currently have an infection that requires antibiotic treatment.
  • People who have taken probiotic supplements or products in the three months before joining.
  • People who have a blocked airway caused by the cancer, a cavity within the tumour, or active tuberculosis.
  • People who have bronchiectasis (a chronic lung condition), an active lung infection, scarring of the lung tissue (pulmonary fibrosis), or diabetes that is not well controlled.
  • People who have another cancer originating in a different part of the body.
  • People who have already received chemotherapy or any other cancer treatment before joining the trial.
  • People whose brain scans (MRI with contrast dye) confirm cancer has spread to the brain before joining.
  • People who have an active or pre-existing condition where the immune system attacks the body (autoimmune disease).
  • People who have serious uncontrolled health conditions, including heart failure, high blood pressure that is not well controlled, unstable chest pain (unstable angina), or a lung condition called interstitial lung disease.
  • People who test positive for hepatitis B or hepatitis C and require treatment for it.
  • People who have a known history of, or test positive for, HIV or AIDS.
  • People who have a known allergy to any of the components of the study medications.
  • People who are pregnant or breastfeeding.
  • People who have previously been treated with certain types of immunotherapy drugs that target specific immune checkpoint proteins (anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: science and technology center, China-Japan Friendship Hospital

Phone: +86 84206264

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Capital Medical University
Registry
ClinicalTrials.gov
Start date
25 September 2024
Est. completion
31 December 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Major pathological response (mPR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov